ClinConnect ClinConnect Logo
Search / Trial NCT06856343

REBECCA Real-world Early BrEast CanCer mAnagement

Launched by ASTRAZENECA · Feb 26, 2025

Trial Information

Current as of July 22, 2025

Recruiting

Keywords

ClinConnect Summary

The REBECCA trial is a study taking place in France that looks at how well a medication called olaparib works for patients with a specific type of breast cancer known as HER2-negative early breast cancer (eBC). This study is observational, meaning the researchers will be watching how patients respond to the treatment rather than assigning them to different treatment groups. The trial is currently recruiting participants who are 18 years or older and are planning to start olaparib treatment based on their doctor's advice.

To be eligible for the study, patients must be diagnosed with HER2-negative eBC and must agree to participate after being informed about the study. If someone is not comfortable with the idea of being part of the trial or is already part of another program for early access to treatments, they won't be able to join. Participants in this study can expect regular check-ins to monitor their health and response to the treatment, helping researchers gather important information about how olaparib works in real-world settings.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Male or female aged ≥ 18 years
  • Patient diagnosed with HER2-negative eBC
  • Patient about to be initiated with adjuvant Olaparib at their physician's discretion
  • Patient has been informed and does not object to participation in the study.
  • Exclusion Criteria:
  • Patient not consenting to participate.
  • Patients included in the Early Access Program

About Astrazeneca

AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.

Locations

Montpellier, , France

Montpellier Cedex 5, , France

Lille Cedex, , France

Caen, , France

Grenoble, , France

Perigueux, , France

Chambray Les Tours, , France

Dechy, , France

Salouel, , France

Paris Cedex 14, , France

Creil Cedex 1, , France

Nancy, , France

Beuvry, , France

Poitiers Cedex, , France

Lyon Cedex 04, , France

Gleize, , France

Limoges Cedex 1, , France

St Brieuc Cedex 1, , France

Thonon Les Bains, , France

Valence, , France

Avignon Cedex 9, , France

Compiegne Cedex, , France

Le Blanc Mesnil, , France

Osny, , France

St Doulchard, , France

St Martin Boulogne, , France

Champigny Sur Marne Cedex, , France

Marseille Cedex 05, , France

St Priest En Jarez Cedex, , France

Fort De France Cedex, , France

Nice Cedex 2, , France

Rouen Cedex, , France

Beauvais Cedex, , France

Metz Tessy, , France

Valence Cedex 9, , France

Frejus Cedex, , France

Argenteuil Cedex, , France

St Gregoire Cedex, , France

St Pierre Cedex, , France

Agen Cedex 9, , France

Bezannes, , France

Clermont Ferrand Cedex 2, , France

Plerin Cedex, , France

St Etienne Cedex 2, , France

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported